Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21516
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 361–372 of 21,516 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
24
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Not yet recruiting Phase 1 Interventional

Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)

NCT07927491
View directory record Official record
Conditions
Recurrent Glioblastoma With EGFR Mutation
Interventions
CM93
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Lenalidomide
Drug
Lead sponsor
European Myeloma Network B.V.
Network
Eligibility
18 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
39
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 11 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Not applicable Interventional

Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury

NCT06848140
View directory record Official record
Conditions
Traumatic Brain Injury, Word Finding Difficulty, Cognitive Symptom, Cognitive Change, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 3 Interventional

Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency

NCT07928388
View directory record Official record
Conditions
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions
Pyridoxal 5'-Phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

NCT07266428
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OTP-01
Drug
Lead sponsor
Ottimo Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Not yet recruiting Early Phase 1 Interventional

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

NCT06957821
View directory record Official record
Conditions
Carotid Artery Diseases, Peripheral Arterial Disease
Interventions
Pegulicianine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 2 Interventional

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459
View directory record Official record
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions
Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
Biological · Drug · Other
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Irvine, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 1 Interventional

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

NCT03750513
View directory record Official record
Conditions
Anaplastic Ependymoma, Ependymoma
Interventions
Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST
Recruiting Phase 2 Interventional

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

NCT06632600
View directory record Official record
Conditions
Chagas Disease
Interventions
LXE408, Placebo, Benznidazole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Sylmar, California • Gainesville, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 4:00 AM EST